BackAlnylam Pharmaceuticals Overview

Alnylam Pharmaceuticals Receivables

Track Alnylam Pharmaceuticals's receivables ($910M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$912.74M
↑ 60.95% YoYΔ $345.63M vs prior year quarter

Peer trimmed avg / median

Loading

Alnylam Pharmaceuticals Receivables History

Loading

Alnylam Pharmaceuticals vs. peers: Receivables Comparison

Loading

Alnylam Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Alnylam Pharmaceuticals (ALNY) FAQ

As of the most recent data (June 2026), ALNY shows a receivables of $910M. That compares with $570M in the prior-year period — up 60.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ALNY's receivables is now $910M (was $570M) — a 60.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Alnylam Pharmaceuticals is outperforming or lagging.

Tracking ALNY's receivables over time shows whether Alnylam Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $910M That compares with $570M in the prior-year period — up 60.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Alnylam Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $910M) with ownership activity and broader fundamentals.

Alnylam Pharmaceuticals's receivables is $910M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.